Enanta Pharmaceuticals, Inc. (ENTA) Stock Grade

About Enanta Pharmaceuticals, Inc.'s fundamentals

Enanta Pharmaceuticals is a small-cap biotechnology company with a market capitalization of $366.8 million that reported negative revenue growth of -3.4% year-over-year, indicating declining sales. The company is currently unprofitable, posting a net loss in its latest annual statement and operating at a net margin of -125.4%, meaning expenses substantially exceed revenues. The company does not pay a dividend and lacks traditional valuation metrics like P/E ratio and return on equity due to its loss-making status.